Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

78 results about "Asymptomatic" patented technology

In medicine, a disease is considered asymptomatic if a patient is a carrier for a disease or infection but experiences no symptoms. A condition might be asymptomatic if it fails to show the noticeable symptoms with which it is usually associated. Asymptomatic infections are also called subclinical infections. Other diseases (such as mental illnesses) might be considered subclinical if they present some but not all of the symptoms required for a clinical diagnosis. The term clinically silent is also used.

Application of serum and cerebrospinal fluid FcRL2 protein in preparation of neurosyphilis or nerve injury diagnosis product

The invention relates to the technical field of biological medicines, in particular to FcRL2 as a serum marker or cerebrospinal fluid marker for early diagnosis, screening and typing detection of neurosyphilis patients. The FcRL2 protein is one of receptor superfamily members, Fc receptor-like glycoproteins, and is related to immune response regulation and immune cell functions. According to the invention, the concentration of the FcRL2 protein in serum or cerebrospinal fluid is used as an index for early diagnosis of neurosyphilis, typing detection of symptomatic neurosyphilis, asymptomatic neurosyphilis, neurosyphilis and recessive syphilis, evaluation of nerve injury degree and the like; the index can be independently used or used as a main reference index to be combined with other indexes to complete diagnosis screening, typing and nerve injury evaluation of the neurosyphilis. Compared with the prior art, the FcRL2 not only has high sensitivity, but also can diagnose the neurosyphilis through noninvasive serum detection, and is beneficial to diagnosis and management of the neurosyphilis in community hospitals and local hospitals.
Owner:BEIJING DITAN HOSPITAL CAPITAL MEDICAL UNIVERSTY

Microbial and human cell-free DNA biomarkers for diagnosing and assessing the severity of inflammatory bowel disease

Disclosed herein in some embodiments are methods, compositions, and systems for distinguishing between ulcerative colitis (UC), Crohn's disease (CD) and other Inflammatory Bowel Disorders (IBD) by sequencing cell free nucleic acids. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether UC, CD, or other IBD are asymptomatic, in remission, or active. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether an active form of UC, CD, or other IBD is mild, moderate, or severe.
Owner:KARIUS INC

Application of CLM-6 protein in preparation of neurosyphilis or nerve injury diagnosis product

PendingCN119291197ANoninvasive Serum TestingIncreased sensitivityDisease diagnosisBiological testingSerum markersAsymptomatic neurosyphilis
The invention relates to the technical field of biological medicines, in particular to a CLM-6 protein (CMRF35-l ike molle 6) as a serum marker or cerebrospinal fluid marker for early diagnosis, screening and typing detection of a neurosyphilis patient. According to the invention, the concentration of CLM-6 protein in cerebrospinal fluid or serum is used as an index for early diagnosis of neurosyphilis, typing detection of symptomatic neurosyphilis, asymptomatic neurosyphilis, neurosyphilis and recessive syphilis, nerve injury degree evaluation and the like; the index can be independently used or used as a main reference index to be combined with other indexes to finish the diagnosis screening and typing of the neurosyphilis and the evaluation of nerve injury. Compared with the prior art, the CLM-6 not only has higher sensitivity, but also can realize noninvasive serum detection on the neurosyphilis, is convenient to detect, and is more beneficial to early diagnosis and management of the neurosyphilis in community hospitals and local hospitals.
Owner:BEIJING DITAN HOSPITAL CAPITAL MEDICAL UNIVERSTY

Collection, assessment and early detection of human lung cancer biomarkers in exhaled breath condensates of mouse animal models

PendingUS20240410022A1Microbiological testing/measurementSensorsHeterograftsTransgene
The present disclosure provides a single mouse exhaled breath collection device and proof-of-concept analyses utilizing an ultra-sensitive and customizable EV purification assay, EV-CATCHER® (Extracellular Vesicle Capture by AnTibody of CHoice and Enzymatic Release) assay. Preliminary studies show that this assay work well for the isolation of exhaled extracellular vesicles (exh-EVs) from exhaled breath condensates (EBC) to capture and characterize miRNAs contained in exh-EVs. Because assembling a large enough cohort of asymptomatic subjects requires time, a complementary approach of using humanized animal models has been chosen to comprehensively assess the robustness and sensitivity of transcriptomic (miRNA and mRNA) and proteomic biomarkers contained in tumor exh-EVs and to enable sensitive detection of human primary and secondary lung cancers during their early development. The results of preliminary analyses demonstrate that the purification of exh-EVs with EV-CATCHER® offers specificity and sensitivity, which will be critical for the targeted purification of tumor exh-EVs from the EBC of transgenic, orthotopic, and Patient-Derived Xenograft (PDX) animal models of human lung cancers.
Owner:HACKENSACK MERIDIAN HEALTH INC

Application of SKR3 protein in preparation of neurosyphilis or nerve injury diagnosis product

The invention relates to the technical field of biological medicines, in particular to a method for using a serine / threonine protein kinase receptor R3 (serine / threonine-protein kinase receptor R3, SKR3) as a cerebrospinal fluid marker for early diagnosis, screening and typing detection of a neurosyphilis patient. According to the invention, the concentration of the SKR3 protein in cerebrospinal fluid or serum is used as an index for early diagnosis of neurosyphilis, typing detection of symptomatic neurosyphilis, asymptomatic neurosyphilis, neurosyphilis and recessive syphilis, nerve injury degree evaluation and the like; the index can be independently used or used as a main reference index to be combined with other indexes to complete diagnosis screening, typing and nerve injury evaluation of the neurosyphilis. The sensitivity of the SKR3 as the marker is high, early warning and screening of the asymptomatic neurosyphilis can be achieved, and medical staff can give a reasonable treatment scheme to patients suffering from the asymptomatic neurosyphilis as early as possible.
Owner:BEIJING DITAN HOSPITAL CAPITAL MEDICAL UNIVERSTY

Application of cerebrospinal fluid GZMA protein in preparation of neurosyphilis or nerve injury diagnosis product

The invention relates to the technical field of biological medicines, in particular to Granzyme A (GZMA) as a cerebrospinal fluid marker for early diagnosis, screening and typing detection of neurosyphilis patients. According to the invention, the concentration of GZMA protein in cerebrospinal fluid is used as an index for early diagnosis of neurosyphilis, typing detection of asymptomatic neurosyphilis, neurosyphilis and recessive syphilis, evaluation of nerve injury degree and the like; the index can be independently used or used as a main reference index to be combined with other indexes to complete diagnosis screening, typing and nerve injury evaluation of the neurosyphilis. Compared with the prior art, the GZMA not only has higher sensitivity, but also can realize auxiliary diagnosis of the asymptomatic neurosyphilis, and is more beneficial to diagnosis and intervention of the asymptomatic neurosyphilis as early as possible.
Owner:BEIJING DITAN HOSPITAL CAPITAL MEDICAL UNIVERSTY

Infected case real-time monitoring system and method

The invention discloses an infected case real-time monitoring system and method, and relates to the technical field of medical treatment, through analysis of a characteristic difference factor Tcyz, an asymptomatic infected patient and a normal healthy patient can be preliminarily distinguished, the analysis process is based on cross comparison of pathological data and behavior data, a potential asymptomatic infected patient can be identified, and the accuracy of diagnosis and treatment is improved. And preliminary estimation is provided for the infection risk of the patient, so that the patient is ensured to enter a to-be-audited mechanism before symptoms appear, and the risk of missed diagnosis is reduced. The natural language processing technology is used for analyzing infection classification of the patient to be verified, and the limitation of a traditional method in patient record processing is overcome. According to the NLP technology, a large amount of unstructured clinical text data such as medical records, medical advices and laboratory reports are automatically processed, relevant information can be rapidly extracted from the unstructured clinical text data, infection types of patients are preliminarily classified, and the infection possibility is judged based on a judgment coefficient Pdxs.
Owner:JILIN UNIV FIRST HOSPITAL

Application of cerebrospinal fluid CTSC protein as marker in preparation of neurosyphilis or nerve injury diagnosis product

The invention relates to the technical field of biological medicine, in particular to application of cerebrospinal fluid CTSC protein as a marker in preparation of neurosyphilis or nerve injury diagnosis products. The CTSC protein is also called Dipetidyl petidease 1, and according to the research conclusion of the invention, the CTSC protein can be used as a cerebrospinal fluid marker for early diagnosis, screening and typing detection of neurosyphilis patients. By measuring the concentration of CTSC protein in cerebrospinal fluid, the concentration is used as an index for early diagnosis of neurosyphilis, typing detection of symptomatic neurosyphilis, asymptomatic neurosyphilis, neurosyphilis and recessive syphilis, and nerve injury degree evaluation. The index can be independently used or used as a main reference index to be combined with other indexes for completing diagnosis screening, typing and nerve injury evaluation of the neurosyphilis, and the index has the advantages of being good in sensitivity, high in specificity and the like.
Owner:BEIJING DITAN HOSPITAL CAPITAL MEDICAL UNIVERSTY

Collection, assessment and early detection of human lung cancer biomarkers in exhaled breath condensates of mouse animal models

PCT designated stage expiredWO2025019709A2Component separationMicrobiological testing/measurementHeterograftsTransgene
The present disclosure provides a single mouse exhaled breath collection device and proof- of-concept analyses utlizing an ultra- sensitive and customizable EV purification assay, EV- CATCHER® (Extracellular Vesicle Capture by AnTibody of CHoice and Enzymatic Release) assay. Preliminary studies show that this assay work well for the isolation of exhaled extracellular vesicles (exh-EVs) from exhaled breath condensates (EBC) to capture and characterize miRNAs contained in exh-EVs. Because assembling a large enough cohort of asymptomatic subjects requires time, a complementary approach of using humanized animal models has been chosen to comprehensively assess the robustness and sensitivity of transcriptomic (miRNA and mRNA) and proteomic biomarkers contained in tumor exh-EVs and to enable sensitive detection of human primary and secondary lung cancers during their early development. The results of preliminary analyses demonstrate that the purification of exh-EVs with EV-CATCHER® offers specificity and sensitivity, which will be critical for the targeted purification of tumor exh-EVs from the EBC of transgenic, orthotopic, and Patient-Derived Xenograft (PDX) animal models of human lung cancers.
Owner:HACKENSACK MERIDIAN HEALTH INC

Cancer classifier models, machine learning systems and methods of use

Disclosed herein are classifier models, computer implemented systems, machine learning systems and methods thereof for classifying asymptomatic patients into a risk category for having or developing cancer and / or classifying a patient with an increased risk of having or developing cancer into an organ system-based malignancy class membership and / or into a specific cancer class membership.
Owner:COHEN JONATHAN +2

Blood biomarkers of oligodendrocyte-derived exosomes and their use in identifying asymptomatic brain injury

Methods of identifying and assays designed to identify at least one biomolecule from a patient are disclosed that comprise: collecting at least one biofluid from a patient, isolating at least one exosome from the biofluid, and identifying at least one biomolecule from the at least one exosome, wherein the at least one biomolecule is bound to the at least one exosome and is locally released from the patient. In some embodiments, the at least one biomolecule comprises a secretory protein, a neurotrophic factor, a growth factor, a cytokine, a chemokine, a pre-toxic molecule, a toxic molecule, or a combination thereof.
Owner:NANOSOMIX

Plasma exosome marker of TB and application thereof

The invention discloses a plasma exosome marker of tuberculosis (TB) and application of the plasma exosome marker, and belongs to the field of biomedical diagnosis, the plasma exosome marker comprises hsa-miR-451a, hsa-miR-1908-5p and hsa-miR-1268b, the expression of hsa-miR-451a in the plasma exosome of an active TB patient is up-regulated, and the expression of the hsa-miR-451a and the expression of the hsa-miR-451a and the expression of the hsa-miR-1908-5p are down-regulated. The expression levels of the markers are detected by using a droplet digital PCR technology, and a multinomial logistic regression diagnosis model is constructed based on a detection result. Experiments prove that when the three miRNA combinations are used for distinguishing active tuberculosis from healthy control (HC), the area (AUC) under a working characteristic curve of a subject reaches 0.970; when latent tuberculosis infection (LTBI) is distinguished from a healthy control, AUC is 0.971; and when the secondary miRNA combination of the hsa-miR-451a and the hsa-miR-1268b is used for distinguishing the asymptomatic tuberculosis (aTB) from the healthy control, the AUC is 0.880. The TB early diagnosis accuracy is remarkably improved, the non-invasive advantage is achieved, wide application prospects are achieved in the aspects of preparation of diagnostic reagents and kits, clinical diagnosis, disease monitoring and the like, and global tuberculosis prevention and control work is powerfully promoted.
Owner:GUANGDONG PROVINCIAL TUBERCULOSIS CONTROL CENT

Integrated clinical embedded ai system for real-time label-free disease detection: a platform-independent approach with multispectral analysis

A system and method for real-time, label-free, in vitro, and cost-effective early disease detection and classification are disclosed. The system integrates multiple spectroscopic techniques, coupled with a firmware¬ controlled terminal gateway and an advanced clinical Al application. It features a sensor unit for sample stability and an actuator to ensure uniform metabolite distribution in liquid samples. The embedded controller dynamically optimizes spectroscopy parameters and processes data in conjunction with the clinical Al application. This enables the precise detection of diseases, including asymptomatic stages. The system's platform-independent architecture ensures adaptability to diverse healthcare settings, such as point-of-care diagnostics and remote environments, while reducing operational complexity and costs. Its innovative design revolutionizes disease monitoring and diagnostics, enabling early intervention.
Owner:V S RENJITH +1

Application of cerebrospinal fluid CD38 protein and specific antibody thereof in preparation of neurosyphilis or nerve injury diagnosis product

The invention relates to the technical field of biological medicines, in particular to application of cerebrospinal fluid CD38 protein and a specific antibody thereof in preparation of neurosyphilis or nerve injury diagnosis products. By measuring the concentration of CD38 protein in cerebrospinal fluid, the concentration is used as an index for early diagnosis of neurosyphilis, typing detection of symptomatic neurosyphilis, asymptomatic neurosyphilis, neurosyphilis and recessive syphilis, nerve injury degree evaluation and the like; the index can be independently used or used as a main reference index to be combined with other indexes to complete diagnosis screening, typing and nerve injury evaluation of syphilis. Compared with the prior art, the marker has the advantages of good sensitivity, high specificity and the like, and is beneficial to diagnosis and management of neurosyphilis.
Owner:BEIJING DITAN HOSPITAL CAPITAL MEDICAL UNIVERSTY

A method for tracing the incubation period asymptomatic transmission based on the sair model

The application relates to a tracing method for latent period asymptomatic transmission based on an SAIR model, which comprises the following steps: S1, determining a single initial transmission source node in an interpersonal relationship complex network, and transmitting according to the source node according to an SAIR model until a moment t0; S2, randomly selecting a certain number of nodes as observation nodes, and knowing the state of the observation nodes at the moment; S3, screening a candidate source node set in the complex network by using a reverse propagation algorithm according to the state of the partial observation nodes, and the hop distance and the effective distance, and the number of nodes is determined by a sampling method; S4, constructing a dynamic message transmission equation according to the SAIR model, and calculating the probability of the candidate source nodes being in different states at a moment Delta t by using the partial observation nodes; and S5, calculating the likelihood probability of the nodes in the candidate source node set becoming sources by using an average field theory, and the source is the node with the maximum probability. According to the application, the spread of infectious diseases of patients with latent period and asymptomatic can be accurately reflected, and the problem of tracing the source of infection can be solved.
Owner:YANGZHOU UNIV

Substituted 2-aminobenzimidazoles analogs as antibiofilm agents

In one aspect, the disclosure relates to compositions and methods for dispersing exiting Salmonella biofilms and inhibiting formation of Salmonella biofilms. In various aspects, the disclosed compositions can be used in methods of treating a persistent Salmonella infection, including an asymptomatic infection. Such infections can colonize a variety of tissues, including the gall-bladder. Also disclosed are methods of treating typhoid fever. Also disclosed are methods for mitigating or preventing secondary outbreaks of typhoid fever by treating asymptomatic subjects who had been symptomatic for typhoid fever at a previous time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Owner:OHIO STATE INNOVATION FOUND +1

Polypeptide for detecting asymptomatic infection of malaria of plasmodium vivax and application of polypeptide

PendingCN121342919ABiological material analysisPeptidesAsymptomatic malariaImported malaria
The invention belongs to the technical field of molecular biological detection, and relates to a polypeptide for detecting asymptomatic infection of plasmodium vivax malaria and application. The polypeptide for detecting the asymptomatic infection of the malaria of the plasmodium vivax is an amino acid sequence as shown in SEQ ID No.1, or a homologous sequence which is subjected to substitution, deletion or insertion of one or more amino acids or has the sequence similarity greater than 75%. The polypeptide has an amino acid sequence as shown in SEQ ID No. 1. The polypeptide SEQ ID No.1 in the invention specifically detects asymptomatic tertian malaria infection, and can effectively deal with tertian malaria input threats in the Burmese border area. Meanwhile, the polypeptide can be coated in a detection tool of a rapid detection kit, and the tool has the characteristics of portability, high efficiency, low cost and the like, and is suitable for field sample detection in a malaria prevalence area.
Owner:SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE

Biomarkers for diagnosing the subclinical phase of alzheimer's disease and uses thereof

To provide molecular signatures of the asymptomatic phase of Alzheimer's disease, methods for diagnosing the asymptomatic phase of Alzheimer's disease in a subject, for predicting the progression of the asymptomatic phase of Alzheimer's disease and for determining a personalized course of treatment in a subject suffering from the asymptomatic phase of Alzheimer's disease, and a computer system comprising a machine learning algorithm trained to diagnose the asymptomatic phase.SOLUTION: The computer system comprises the steps of receiving inputs of the levels, amounts or concentrations of the at least five biomarkers as determined in a sample obtained from the subject, analyzing and transforming the inputs of the levels, amounts or concentrations of the at least five biomarkers by organizing and / or modifying each level, amount or concentration input via a machine learning algorithm to derive a probability score and / or a classification label, and generating an output which is a classification label or a probability score.SELECTED DRAWING: Figure 7
Owner:AGENT INSURANCE GRP INC

Construction method of colorectal adenoma prediction model and colorectal adenoma prediction system

According to the construction method of the colorectal adenoma prediction model and the colorectal adenoma prediction system provided by the invention, 14 kinds of colorectal adenoma related living habits and two kinds of colorectal adenoma related intestinal bacteria are found by collecting and analyzing the living habits and intestinal flora information of colorectal adenoma and healthy control people; the abundance information of the living habits and intestinal bacteria can be used as markers to jointly predict the occurrence risk of colorectal adenoma. The method is high in prediction accuracy, convenient, efficient, low in cost and suitable for wide screening in large asymptomatic people, and the problem that colorectal adenoma is difficult to screen can be solved.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

An exosomal characteristic protein composition for diagnosing HIV-related asymptomatic neurocognitive disorders and its application

This invention discloses an exosome characteristic protein composition for diagnosing HIV-related asymptomatic neurocognitive impairment (ANI), comprising the following characteristic proteins: DSCAM, IGF1, CAMK2D, UPF1, ALDH2, and EIF5A. Compared with non-ANI individuals, the relative abundance of DSCAM and IGF1 is increased in ANI individuals, while the relative abundance of CAMK2D, UPF1, ALDH2, and EIF5A is decreased. This exosome characteristic protein composition has the following advantages: (1) high diagnostic accuracy, comprehensively covering the core pathways of ANI pathological mechanisms, and accurately identifying ANI patients; (2) high specificity, clearly reflecting the specific expression patterns of exosome proteins in ANI patients, thereby effectively distinguishing ANI from NCI and healthy individuals; (3) non-invasive and convenient, based on peripheral plasma testing, improving subject compliance, and suitable for large-scale screening and long-term follow-up; (4) easy clinical translation: the kits prepared for the above exosome characteristic proteins are easy to operate, can be mass-produced and used, and can be implemented in hospitals and disease control centers at all levels, making them suitable for widespread application.
Owner:BEIJING YOUAN HOSPITAL CAPITAL MEDICAL UNIV

Application of cerebrospinal fluid CD38 protein and its specific antibody in the preparation of diagnostic products for neurosyphilis or nerve damage

ActiveCN119438605BDisease diagnosisBiological testingAsymptomatic neurosyphilisNeurological injury
The present invention relates to the field of biomedical technology, and specifically to the use of cerebrospinal fluid CD38 protein and its specific antibody in the preparation of neurosyphilis or nerve damage diagnosis products. By measuring the concentration of CD38 protein in cerebrospinal fluid, the concentration is used as an indicator for early diagnosis of neurosyphilis, symptomatic neurosyphilis, asymptomatic neurosyphilis, typing detection of neurosyphilis and latent syphilis, and evaluation of the degree of nerve damage. The indicator can be used alone or as a main reference indicator in combination with other indicators to complete the diagnostic screening, typing and nerve damage evaluation of syphilis. Compared with the existing technology, this marker has the advantages of good sensitivity and high specificity, which is conducive to the diagnosis and management of neurosyphilis.
Owner:BEIJING DITAN HOSPITAL CAPITAL MEDICAL UNIVERSTY

Markers for detecting lung cancer and their uses and systems

The present invention discloses a marker for detecting lung cancer, its use, and a system. The marker and system can: 1) be used non-invasively for early screening of asymptomatic individuals and prognostic assessment of cancer patients, reducing the risks associated with invasive testing; and 2) offer increased sensitivity and accuracy, enabling real-time monitoring.
Owner:BIOCHAIN BEIJING SCI & TECH

Systems, methods, and devices for detecting viral respiratory illness in presymptomatic and asymptomatic infected persons

Disclosed herein are systems, methods, and devices of detecting illness in presymptomatic and asymptomatic infected persons using wearable sensor technology. In a first embodiment, a method is implemented on a computing device, the method includes receiving first sensor data associated with the person over a first period of time and applying the first sensor data to a multi-variate detection model. The method further includes receiving second sensor data associated with the person over a second period of time and applying the second sensor data to the multi-variate detection model. Further the method includes determining a probability value of the illness in the person using the multi-variate detection model and transmitting the probability value to a user interface (UI).
Owner:RES TRIANGLE INST

Diagnosis of congenital cytomegalovirus infection

ActiveUS12504429B2Disease diagnosisCytomegalovirus infectionsMedicine
The present invention provides biomarkers allowing the diagnosis of symptomatic congenital cytomegalovirus (CMV) infection and in particular to differentiate between symptomatic and asymptomatic infected fetuses, methods of diagnosis of CMV using said biomarkers, diagnostic kits comprising thereof, and use of the kits and methods of diagnosing fetuses infected with a symptomatic congenital cytomegalovirus (CMV).
Owner:HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD

Combination assay of cytokines and human antibodies to map for the diagnosis of crohns disease, tuberculosis, and other bacterial diseases

A system or method for a combination assay of human antibodies to Mycobacterium avium subsp. paratuberculosis (MAP) and cytokines for the diagnosis of Crohn's disease, tuberculosis, and other bacterial diseases in symptomatic and asymptomatic individuals is provided herein. The system or method describes generally using a combination of human antibodies to MAP useful for the detection of a MAP infection in human blood samples and cytokines secreted by the human host with a MAP infection to provide a simple and rapid serological test which can diagnose patients with Crohn's disease and can aid in the selection of patients for certain antibiotic therapies. A similar system could be used for the diagnosis and selection for therapy of tuberculosis and other mycobacterial or bacterial diseases.
Owner:KUENSTNER JOHN TODD +1

Early detection of hepatocellular carcinoma

The present invention relates to early detection of hepatocellular carcinoma. Specifically, the present invention provides methods, assays, and kits for detecting hepatocellular carcinoma, as well as methods for stratifying subjects into higher risk and lower risk categories for developing hepatocellular carcinoma, and methods for treating and managing subjects suspected of having or at risk for developing hepatocellular carcinoma. While previous work has attempted to address the need for highly sensitive early predictive indicators for hepatocellular carcinoma by evaluating one or more biological factors, none has approached the sensitivity required for a clinically relevant determination of whether a subject, particularly an asymptomatic subject, has the disease. The inventors have discovered that certain combinations of factors meet this need by conferring previously unattainable levels of high accuracy.
Owner:DREXEL UNIV

Collection, assessment and early detection of human lung cancer biomarkers in exhaled breath condensates of mouse animal models

The present disclosure provides a single mouse exhaled breath collection device and proof- of-concept analyses utlizing an ultra- sensitive and customizable EV purification assay, EV- CATCHER® (Extracellular Vesicle Capture by AnTibody of CHoice and Enzymatic Release) assay. Preliminary studies show that this assay work well for the isolation of exhaled extracellular vesicles (exh-EVs) from exhaled breath condensates (EBC) to capture and characterize miRNAs contained in exh-EVs. Because assembling a large enough cohort of asymptomatic subjects requires time, a complementary approach of using humanized animal models has been chosen to comprehensively assess the robustness and sensitivity of transcriptomic (miRNA and mRNA) and proteomic biomarkers contained in tumor exh-EVs and to enable sensitive detection of human primary and secondary lung cancers during their early development. The results of preliminary analyses demonstrate that the purification of exh-EVs with EV-CATCHER® offers specificity and sensitivity, which will be critical for the targeted purification of tumor exh-EVs from the EBC of transgenic, orthotopic, and Patient-Derived Xenograft (PDX) animal models of human lung cancers.
Owner:HACKENSACK MERIDIAN HEALTH INC

Identification method of asymptomatic infection of strawberry anthracnose based on hyperspectral features

The present invention discloses a method for identifying asymptomatic anthracnose infection in strawberries based on hyperspectral features. The method specifically includes collecting raw spectral feature data and preprocessing the spectral data, screening characteristic wavelengths for detecting asymptomatic anthracnose infection in strawberries, and constructing asymptomatic anthracnose identification models for strawberries using random forests and BP neural networks based on the characteristic wavelengths. The constructed models can non-destructively, quickly, and accurately identify anthracnose-infected strawberry plants during the asymptomatic period. The model constructed based on random forests has a higher recognition rate, while the model constructed using the BP neural network recognition model has higher recognition efficiency and faster speed. In production, an appropriate strawberry disease identification model can be selected according to different needs. The present invention achieves a breakthrough in strawberry disease identification, saves time and the cost of traditional biochemical analysis, improves economic benefits, achieves cost reduction, and conforms to the green and sustainable development of agriculture.
Owner:JIANGSU ACAD OF AGRI SCI +1

Application of D-sorbitol in screening of esophageal squamous cell carcinoma

The present invention belongs to the field of biomedicine technology, and discloses a marker for esophageal squamous cell carcinoma screening and its application. The marker for esophageal squamous cell carcinoma screening provided by the present invention is D-sorbitol or N-o-toluic acid glycine or a combination of D-sorbitol and N-o-toluic acid glycine, and the detection reagent of the marker can be used to prepare an esophageal squamous cell carcinoma screening product. The present invention also provides a kit for esophageal squamous cell carcinoma screening, and the kit contains a detection reagent for detecting the above-mentioned marker. The present invention can effectively detect esophageal squamous cell carcinoma, especially early esophageal squamous cell carcinoma, by detecting the expression level of D-sorbitol or N-o-toluic acid glycine or a combination of D-sorbitol and N-o-toluic acid glycine in human serum; when D-sorbitol is combined with N-o-toluic acid glycine, its detection sensitivity is as high as 90.0%, and the specificity reaches 85.7%, which can be used for large-scale screening of asymptomatic people in high-incidence areas of esophageal squamous cell carcinoma, which is conducive to screening and early detection of asymptomatic high-risk people.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV

Techniques for screening and monitoring patients for aortic aneurysms

ActiveUS12661015B2CatheterSensorsDiseaseAortic aneurysm screening
An aortic aneurysm carries increasing risk of rupture with growing aneurysm diameter. This condition is typically asymptomatic, so screening and surveillance are essential. Ultrasound and other imaging methods are employed for such monitoring at high accuracy. However, these methods require an expert and are expensive. Aortic aneurysms are considerably under-detected at present and may become even more under-detected in the future as the disease prevalence increases with societal aging. This disclosure present devices that are convenient in use and cost for aortic aneurysm screening and surveillance.
Owner:UNIV OF MARYLAND +1